FindTrial
Sign In

Piperacillin-tazobactam combination product

DRUG8 trials

Sponsors

West Virginia University, Chinese PLA General Hospital, The University of Queensland, Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva, Karolinska Institutet

Conditions

Bloodstream InfectionsCholecystitis, AcuteCritical IllnessCystic FibrosisFebrileHematopoietic Stem Cell TransplantationInfectionNeutropenia

Phase 3

Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis
CompletedNCT02619149
Karolinska InstitutetCholecystitis, Acute
Start: 2009-03-31End: 2018-01-31Updated: 2018-03-06

Phase 4

Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
TerminatedNCT01694069
West Virginia UniversityCystic Fibrosis
Start: 2012-09-30End: 2013-09-30Updated: 2022-02-01
RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.
TerminatedNCT02176122
The University of QueenslandBloodstream Infections
Start: 2014-02-28End: 2017-08-07Updated: 2017-11-27
Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response
CompletedNCT02437045
The University of QueenslandBloodstream Infections
Start: 2015-04-30End: 2020-12-31Target: 100Updated: 2023-05-10

Unknown Phase

Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
NCT01714557
Chinese PLA General HospitalHematopoietic Stem Cell Transplantation, Neutropenia
Start: 2012-09-30End: 2014-11-30Target: 150Updated: 2012-10-26
Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia
CompletedNCT01714570
Chinese PLA General HospitalFebrile, Hematopoietic Stem Cell Transplantation, Neutropenia
Start: 2012-11-30End: 2014-04-30Updated: 2014-04-17
AbioKin - Antibiotic Kinetics
CompletedNCT02609646
Gruppo Italiano per la Valutazione degli Interventi in Terapia IntensivaCritical Illness, Infection
Start: 2016-01-31End: 2020-06-26Updated: 2021-01-19
LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients
TerminatedNCT02840136
University GhentCystic Fibrosis
Start: 2016-02-29End: 2017-09-01Updated: 2021-12-15

Related Papers

Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing <i>Enterobacter</i> spp, <i>Citrobacter freundii</i>, <i>Morganella morganii</i>, <i>Providencia</i> spp, or <i>Serratia marcescens</i>: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)
Open Forum Infectious Diseases2021-08-0185 citations
Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial
Trials2021-04-2222 citations
Antibiotic prophylaxis in acute cholecystectomy revisited: results of a double-blind randomised controlled trial.
2020-08-2910 citations
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance
JAMA2018-09-11731 citations
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
2015-01-2750 citations